Status:
RECRUITING
PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma
Lead Sponsor:
National Research Center for Hematology, Russia
Conditions:
Hodgkin Lymphoma
Hodgkin Disease
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
Brief Summary
This is a single-center, open-label, phase 2 pilot study evaluating the efficacy and safety of a response-adapted first-line treatment strategy for patients with classical Hodgkin lymphoma (cHL) and u...
Detailed Description
The FINISH study (First-line Immuno-chemotherapy Navigated by Interim PET for Stratification and Hazard minimization In Hodgkin lymphoma) is designed to evaluate a novel personalized treatment strateg...
Eligibility Criteria
Inclusion
- Signed written informed consent prior to any study-specific procedures
- Histologically confirmed classical Hodgkin lymphoma (cHL)
- Newly diagnosed disease, Ann Arbor stage IIB (bulky), III, or IV
- At least one measurable lesion ≥15 mm in the longest diameter (by CT)
- Age between 18 and 60 years (inclusive)
- ECOG performance status 0-2
- PET-CT performed at baseline
- No prior chemotherapy, radiotherapy, or immunotherapy for lymphoma
- Adequate organ function, including:
- Serum creatinine ≤ 0.2 mmol/L
- Absence of severe cardiac, pulmonary, hepatic, or renal dysfunction
- Ability to comply with the study protocol and scheduled visits
Exclusion
- Active hepatitis B or C infection
- Positive test for HIV
- Pregnancy or breastfeeding
- Prior or active autoimmune disease requiring systemic therapy
- Vaccination with a live vaccine within 30 days prior to first nivolumab dose
- History of non-infectious pneumonitis requiring corticosteroids
- Prior malignancy (except for adequately treated basal cell carcinoma or cervical carcinoma in situ)
- Congestive heart failure, unstable angina, recent myocardial infarction, or severe cardiac arrhythmias
- Severe renal impairment (serum creatinine \> 0.2 mmol/L), unless lymphoma-related
- Severe hepatic dysfunction, unless directly related to lymphoma
- Severe pneumonia with respiratory failure or hypoxemia not corrected within 2-3 days
- Sepsis or hemodynamic instability
- Life-threatening bleeding events (e.g., gastrointestinal or cerebral hemorrhage)
- Cachexia (total serum protein \< 35 g/L), unless due to lymphoma-related liver damage
- Decompensated diabetes mellitus
- Any somatic or psychiatric condition that, in the investigator's judgment, precludes informed consent or study participation
Key Trial Info
Start Date :
July 29 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2028
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT07209059
Start Date
July 29 2025
End Date
December 1 2028
Last Update
October 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Medical Research Center for Hematology
Moscow, Russia, 125167